Back to top

oncology-screening: Archive

Zacks Equity Research

Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy

Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca.

AZNPositive Net Change MRKNegative Net Change FUSNPositive Net Change ALLOPositive Net Change

Shaun Pruitt

Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition

Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.

PFEPositive Net Change SGENPositive Net Change

Zacks Equity Research

Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review

Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA

REGNPositive Net Change SNYPositive Net Change CRSPNegative Net Change ALLOPositive Net Change

Kevin Cook

Bull of the Day: Lantheus (LNTH)

Stunning "beat-and-raise" quarter has analysts scrambling to raise estimates and price targets above $110

LNTHPositive Net Change

Zacks Equity Research

Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?

On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.

ICPTPositive Net Change SNDXPositive Net Change BGNEPositive Net Change IMCRPositive Net Change